Arrowhead Pharmaceuticals Inc. (ARWR)

21.97
NASDAQ : Health Technology
Prev Close 21.79
Day Low/High 20.42 / 22.08
52 Wk Low/High 9.56 / 22.74
Avg Volume 1.58M
Exchange NASDAQ
Shares Outstanding 94.81M
Market Cap 2.07B
EPS -0.70
P/E Ratio 311.29
Div & Yield N.A. (N.A)
Arrowhead Announces Proposed Underwritten Offering Of Common Stock

Arrowhead Announces Proposed Underwritten Offering Of Common Stock

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced its intention to offer and sell shares of its common stock in an underwritten offering...

Arrowhead Reports Fiscal 2014 First Quarter Financial Results

Arrowhead Reports Fiscal 2014 First Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted therapeutics, today announced financial results for its fiscal 2014 first quarter ended December 31, 2013.

Arrowhead To Participate In Panel Discussions At 16th Annual BIO CEO & Investor Conference

Arrowhead To Participate In Panel Discussions At 16th Annual BIO CEO & Investor Conference

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that members of management will be panelists on two panel discussions at the 16 th...

Arrowhead To Report Fiscal 2014 First Quarter Financial Results

Arrowhead To Report Fiscal 2014 First Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2014 first quarter ended...

3 Stocks Rising on Big Volume

3 Stocks Rising on Big Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

It's Lunchtime at the J.P. Morgan Healthcare Confab. Here's What I Learned So Far

It's Lunchtime at the J.P. Morgan Healthcare Confab. Here's What I Learned So Far

Here are some random thoughts and observations from what I saw and heard this morning. Totally off the cuff stuff on Celgene, InterMune, Alnylam, NPS Pharma and Seattle Genetics.

Biotech 2013 by the Numbers: A Blockbuster Year

Biotech 2013 by the Numbers: A Blockbuster Year

The biotech sector closed 2013 up 65%, greatly outperforming the broader markets.

Taken by Surprise

The conventional wisdom on Fed tapering proves wrong.

Arrowhead Reports Fiscal 2013 Fourth Quarter And Year-End Financial Results

Arrowhead Reports Fiscal 2013 Fourth Quarter And Year-End Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2013 fourth quarter and year ended September 30, 2013.

5 Stocks Set to Soar on Bullish Earnings

5 Stocks Set to Soar on Bullish Earnings

These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.

Arrowhead To Report Fiscal 2013 Fourth Quarter And Year-End Financial Results

Arrowhead To Report Fiscal 2013 Fourth Quarter And Year-End Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2013 fourth quarter and year...

Arrowhead Presents Phase 1 Data On ARC-520 At HepDART 2013

Arrowhead Presents Phase 1 Data On ARC-520 At HepDART 2013

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that COO and Head of R&D, Bruce Given, M.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to trade higher from current levels.

Arrowhead To Present At Piper Jaffray Healthcare Conference

Arrowhead To Present At Piper Jaffray Healthcare Conference

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that President and CEO, Christopher Anzalone, Ph.

Arrowhead Submits Application To Begin Phase 2a Trial Of ARC-520 For The Treatment Of Chronic Hepatitis B Infection

Arrowhead Submits Application To Begin Phase 2a Trial Of ARC-520 For The Treatment Of Chronic Hepatitis B Infection

Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a phase 2a clinical trial of...

Arrowhead To Present At Upcoming Conferences

Arrowhead To Present At Upcoming Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will present data on the Dynamic Polyconjugate (DPC) siRNA delivery technology...

Arrowhead Presents Data Suggesting ARC-520 Induces Therapeutic Flare In Chronic Hepatitis B

Arrowhead Presents Data Suggesting ARC-520 Induces Therapeutic Flare In Chronic Hepatitis B

Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it presented new data on ARC-520, its clinical candidate for the treatment of...

Arrowhead Announces Inducement Grants Under NASDAQ Rule 5635(c)(4)

Arrowhead Announces Inducement Grants Under NASDAQ Rule 5635(c)(4)

Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced it awarded "inducement" options to two new employees under Rule 5635(c)(4) of the NASDAQ...

First Week Of June 2014 Options Trading For Arrowhead Research (ARWR)

First Week Of June 2014 Options Trading For Arrowhead Research (ARWR)

Investors in Arrowhead Research Corp saw new options become available this week, for the June 2014 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arrowhead To Present At Upcoming Conferences

Arrowhead To Present At Upcoming Conferences

Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will present data on ARC-520, its hepatitis B drug candidate, at two upcoming...

Arrowhead Closes Private Offering With Net Proceeds Of $60 Million

Arrowhead Closes Private Offering With Net Proceeds Of $60 Million

Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that on October 11, 2013 it closed a previously announced private offering of common and...

Arrowhead Prices At-Market Private Offering For $60 Million Net Proceeds

Arrowhead Prices At-Market Private Offering For $60 Million Net Proceeds

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it has priced a private offering with net proceeds expected to be $60 million.

Arrowhead Completes Enrollment In Phase 1 Study Of ARC-520 For The Treatment Of Chronic Hepatitis B

Arrowhead Completes Enrollment In Phase 1 Study Of ARC-520 For The Treatment Of Chronic Hepatitis B

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based...

Some Weekend Folding Money

Some Weekend Folding Money

I'm content to head into the weekend with my short-term book mostly on the cash side.

Biotech Breakouts

Biotech Breakouts

Favorable charts for Celldex, Repligen and Arrowhead Research.

Arrowhead Promotes David Lewis To Chief Scientific Officer

Arrowhead Promotes David Lewis To Chief Scientific Officer

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced the promotion of David Lewis, Ph.

Arrowhead Reports Fiscal 2013 Third Quarter Financial Results

Arrowhead Reports Fiscal 2013 Third Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2013 third quarter ended June 30, 2013.

Arrowhead To Report Fiscal 2013 Third Quarter Financial Results

Arrowhead To Report Fiscal 2013 Third Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2013 third quarter ended June...

Arrowhead Begins Phase 1 Trial Of RNAi Therapeutic ARC-520 For Treatment Of Chronic Hepatitis B Infection

Arrowhead Begins Phase 1 Trial Of RNAi Therapeutic ARC-520 For Treatment Of Chronic Hepatitis B Infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it has initiated dosing in a Phase 1 clinical trial of ARC-520, the Company’s...

Arrowhead To Present At Upcoming Scientific Conferences

Arrowhead To Present At Upcoming Scientific Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that the company will present data on the Dynamic PolyConjugate™ (DPC) siRNA delivery system and the ARC-520 ...

TheStreet Quant Rating: D (Sell)